NEW YORK and LONDON, May 21, 2018 - Akari Therapeutics, Plc (NASDAQ: AKTX), a biopharmaceutical company focused on the development and commercialization of …
[Read more...] about Akari Therapeutics Receives Notice Related to Delay in 20-F Filing
Akari Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Clinical Progress
Received Regulatory Clearance in Europe to Open First Clinical Trial Site for Phase III PNH Naïve Trial CAPSTONE, the Phase III Naïve PNH Trial Expected to …
Akari Therapeutics to Present at the Leerink Partners Global Healthcare Conference
NEW YORK and LONDON, February 7, 2018 - Akari Therapeutics, Plc (NASDAQ:AKTX) (“Akari” or “the Company”), a biopharmaceutical company focused on the development …
Akari Therapeutics Announces Completion of Phase II COBALT Trial of Coversin in Patients with PNH and Further Progress of Clinical Trials
The final three Paroxysmal Nocturnal Hemoglobinuria (PNH) patients enrolled into the Phase II COBALT trial with the revised dosing regimen had median LDH of …
Akari Therapeutics Strengthens Board with Two Senior Industry Appointments
NEW YORK and LONDON, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc(NASDAQ:AKTX) (“Akari” or “the Company”), a biopharmaceutical company focused on …
[Read more...] about Akari Therapeutics Strengthens Board with Two Senior Industry Appointments
